# Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis

> **NCT03350815** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 322 (actual)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** 150 mg open-label secukinumab
- **DRUG:** 150 mg double-blinded secukinumab
- **DRUG:** 300 mg double-blinded secukinumab

## Key facts

- **NCT ID:** NCT03350815
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-13
- **Primary completion:** 2021-03-11
- **Final completion:** 2021-05-29
- **Target enrollment:** 322 (ACTUAL)
- **Last updated:** 2022-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03350815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03350815, "Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03350815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*